Skip to content
Peptigraph home

Enclomiphene vs Sermorelin: What the Research Shows

Enclomiphene and Sermorelin side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
SERM (not a peptide)Not FDA approved · compoundedEnclomipheneOral SERM (not a peptide), not FDA-approved; in men with secondary hypogonadism it raised morning serum testosterone to levels similar to those obtained with a topical testosterone gel.[19]OtherGHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[20]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Enclomiphene if…

  • you want an oral option with randomized testosterone data against a gel: At 25 mg daily, day-42 testosterone averaged 604 ng/dL versus 500 ng for transdermal testosterone.[4]
  • you want randomized data on sperm concentration versus testosterone gel: Sperm concentration stayed in the normal range with enclomiphene but fell markedly with testosterone gel.[3]

Consider Sermorelin if…

  • you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[20]

What they have in common

  • Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[21]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 8 of 11 fields where the two differ. PCAC vote, Jul 2026, Half-life, Evidence strength are the same or both unknown.

FieldEnclomipheneSermorelin
ClassSERM (not a peptide)GHRH analog
Also calledenclo—
CategoryOtherGrowth hormone
FDA statusNot FDA approved · compoundedCompounded by prescription
WADAProhibited by WADA (S4.2)Enclomiphene is an isomer of clomifene, which is named in S4.2 (anti-estrogens/SERMs, prohibited at all times). Enclomiphene itself is not spelled out in the list text we cached, so this rests on it being a form of clomifene.Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.
Anti-doping detection
  • In a study of men taking clomiphene (a mix of zuclomiphene and enclomiphene), the zuclomiphene isomer stayed detectable in urine for months. The abstract gives no window for enclomiphene itself.PMID 30295816
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Human studies we summarised6 human (4 randomized or controlled) of 9 summarised6 human (1 randomized or controlled) of 9 summarised
Typical study doses

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Enclomiphene and Sermorelin together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Open the stack page

What each was tested for

In the enclomiphene phase 2 study, mean total testosterone at day 42 was 604 ng/dL on enclomiphene citrate 25 mg daily, against 500 ng/dL on transdermal testosterone.[4]

In one enclomiphene study, sperm counts rose in every man tested, at both 3 and 6 months.[24]

An observational comparison found lower odds of adverse events with enclomiphene than clomiphene (OR 0.18, 95% CI 0.07-0.44).[25]

Sermorelin's older-man trial used a different design: healthy men aged 64 to 76 self-injected 2 mg of GHRH nightly for 6 weeks.[14]

In that trial, upright row, shoulder press and abdominal crunch endurance improved; the other strength measures did not.[14]

Safety notes and product status

A recent case report describes new atrial flutter after a man inadvertently doubled his enclomiphene dose, but the authors say causality cannot be established.[5]

That report notes that enclomiphene is increasingly prescribed off-label and that its cardiovascular safety profile remains poorly characterised.[5]

Geref, the recombinant GHRH product, was discontinued by its only US manufacturer, per a 2008 announcement.[26]

Common questions

Enclomiphene vs sermorelin: which should I use?

They are studied for different problems. The enclomiphene trial cited measured testosterone in hypogonadal men; the sermorelin-type GHRH trials cited measured GH-axis hormones in children and older men.[4]

Is enclomiphene taken by injection like sermorelin?

No. Enclomiphene was studied as daily oral doses; the GHRH trial above used nightly subcutaneous self-injection.[3]

Which has more human evidence?

A meta-analysis pooling clomiphene and enclomiphene studies reported a significant testosterone increase with clomiphene (mean difference 11.56 nmol/L). No sermorelin meta-analysis is cited here.[27]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males.The Journal of clinical endocrinology and metabolism · 2019PMID 30295816Accessed 2 Oct 2026
  3. 3Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.BJU international · 2016PMID 26496621Accessed 2 Oct 2026
  4. 4Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.BJU international · 2013PMID 23875626Accessed 2 Oct 2026
  5. 5Newly Detected Atrial Flutter After Enclomiphene Dose Escalation in a Patient With Prior Mitral Valve Repair and Chronic Immune Thrombocytopenia: A Case Report.Cureus · 2026PMID 42741668Accessed 2 Oct 2026
  6. 6PubMed search: enclomiphene[tiab] OR enclomifene[tiab] OR "trans-clomiphene"[tiab] (98 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt] OR meta-analysis[pt]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (hypogonadism[tiab] OR testosterone[tiab]) AND humans[mh] (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (enclomiphene[tiab] OR enclomifene[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  11. 11Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  12. 12Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  13. 13Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  14. 14Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  15. 15PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: (enclomiphene[tiab] OR enclomifene[tiab] OR "trans-clomiphene"[tiab] OR Androxal[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone.Fertility and sterility · 2014PMID 25044085Accessed 2 Oct 2026
  20. 20Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  21. 21Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  22. 22PubMed search: enclomiphene[tiab] OR enclomifene[tiab] OR Androxal[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  23. 23PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  24. 24Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel.The journal of sexual medicine · 2013PMID 23530575Accessed 2 Oct 2026
  25. 25Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.Translational andrology and urology · 2024PMID 39434750Accessed 2 Oct 2026
  26. 26Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026
  27. 27Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis.Andrology · 2023PMID 36604313Accessed 2 Oct 2026

Found an error? Report a correction.